Safety, Tolerability and Pharmacokinetics of a High-Dose, Rapid-Infusion Monoclonal Antibody: Phase I Results for Intravenous Sotrovimab 3000 mg
Authors
- Andrew Skingsley (ORCID: https://orcid.org/0000-0003-4826-4585)
- Asma El‐Zailik (ORCID: https://orcid.org/0000-0002-3621-2211)
- Pradipta Sarkar (ORCID: https://orcid.org/0000-0002-9881-9385)
- Jennifer Moore (ORCID: https://orcid.org/0000-0003-1300-7298)
- Jerzy Daniluk
- Yasmin Sánchez‐Pearson (ORCID: https://orcid.org/0009-0007-6216-6291)
- Farai Moyo
- Alicia Aylott
- Amanda Peppercorn (ORCID: https://orcid.org/0000-0002-9162-2539)
- Sergio Parra (ORCID: https://orcid.org/0000-0002-3191-0475)
- Sookti Bhangu
Institutions
- Age UK (GB)
- Pearson (United Kingdom) (GB)
- GlaxoSmithKline (India) (IN)
- GlaxoSmithKline (Poland) (PL)
- GlaxoSmithKline (Canada) (CA)
- VIR Biotechnology (United States) (US)
- Geotechnical Consulting Group (United Kingdom) (GB)